Pharmacokinetic aspects of retinal drug delivery

Eva M. del Amo, Anna-Kaisa Irmeli Rimpelä, Emma Heikkinen, Otto K. Kari, Eva Ramsay, Tatu Lajunen, Mechthild Schmitt, Laura Pelkonen, Madhushree Bhattacharya, Dominique Richardson, Astrid Subrizi, Tiina Turunen, Mika Reinisalo, Jaakko Itkonen, Elisa Toropainen, Marco G. Casteleijn, Heidi Kidron, Maxim Antopolsky, Kati-Sisko Vellonen, Marika Ruponen & 1 andra Arto Urtti

Forskningsoutput: TidskriftsbidragÖversiktsartikelVetenskapligPeer review

Sammanfattning

Drug delivery to the posterior eye segment is an important challenge in ophthalmology, because many diseases affect the retina and choroid leading to impaired vision or blindness. Currently, intravitreal injections are the method of choice to administer drugs to the retina, but this approach is applicable only in selected cases (e.g. anti-VEGF antibodies and soluble receptors). There are two basic approaches that can be adopted to improve retinal drug delivery: prolonged and/or retina targeted delivery of intravitreal drugs and use of other routes of drug administration, such as periocular, suprachoroidal, sub-retinal, systemic, or topical. Properties of the administration route, drug and delivery system determine the efficacy and safety of these approaches. Pharmacokinetic and pharmacodynamic factors determine the required dosing rates and doses that are needed for drug action. In addition, tolerability factors limit the use of many materials in ocular drug delivery. This review article provides a critical discussion of retinal drug delivery, particularly from the pharmacokinetic point of view. This article does not include an extensive review of drug delivery technologies, because they have already been reviewed several times recently. Instead, we aim to provide a systematic and quantitative view on the pharmacokinetic factors in drug delivery to the posterior eye segment. This review is based on the literature and unpublished data from the authors' laboratory.
Originalspråkengelska
TidskriftProgress in Retinal and Eye Research
Volym57
Sidor (från-till)134-185
Antal sidor52
ISSN1350-9462
DOI
StatusPublicerad - mar 2017
MoE-publikationstypA2 Granska artikel i en vetenskaplig tidskrift

Vetenskapsgrenar

  • 317 Farmaci
  • 3125 Öron-, näs- och halssjukdomar, ögonsjukdomar

Citera det här

del Amo, Eva M. ; Rimpelä, Anna-Kaisa Irmeli ; Heikkinen, Emma ; Kari, Otto K. ; Ramsay, Eva ; Lajunen, Tatu ; Schmitt, Mechthild ; Pelkonen, Laura ; Bhattacharya, Madhushree ; Richardson, Dominique ; Subrizi, Astrid ; Turunen, Tiina ; Reinisalo, Mika ; Itkonen, Jaakko ; Toropainen, Elisa ; Casteleijn, Marco G. ; Kidron, Heidi ; Antopolsky, Maxim ; Vellonen, Kati-Sisko ; Ruponen, Marika ; Urtti, Arto . / Pharmacokinetic aspects of retinal drug delivery. I: Progress in Retinal and Eye Research. 2017 ; Vol. 57. s. 134-185.
@article{add46d27af0c4ac8becfeed2214f26f5,
title = "Pharmacokinetic aspects of retinal drug delivery",
abstract = "Drug delivery to the posterior eye segment is an important challenge in ophthalmology, because many diseases affect the retina and choroid leading to impaired vision or blindness. Currently, intravitreal injections are the method of choice to administer drugs to the retina, but this approach is applicable only in selected cases (e.g. anti-VEGF antibodies and soluble receptors). There are two basic approaches that can be adopted to improve retinal drug delivery: prolonged and/or retina targeted delivery of intravitreal drugs and use of other routes of drug administration, such as periocular, suprachoroidal, sub-retinal, systemic, or topical. Properties of the administration route, drug and delivery system determine the efficacy and safety of these approaches. Pharmacokinetic and pharmacodynamic factors determine the required dosing rates and doses that are needed for drug action. In addition, tolerability factors limit the use of many materials in ocular drug delivery. This review article provides a critical discussion of retinal drug delivery, particularly from the pharmacokinetic point of view. This article does not include an extensive review of drug delivery technologies, because they have already been reviewed several times recently. Instead, we aim to provide a systematic and quantitative view on the pharmacokinetic factors in drug delivery to the posterior eye segment. This review is based on the literature and unpublished data from the authors' laboratory.",
keywords = "317 Pharmacy, 3125 Otorhinolaryngology, ophthalmology, Retina , Vitreous , Choroid , Topical , Intravitreal , Sub-conjunctival , Suprachoroidal , Clearance , Distribution , Pharmacokinetic modeling , Transport , ENDOTHELIAL GROWTH-FACTOR , PIGMENT EPITHELIAL-CELLS , DIABETIC MACULAR EDEMA , SINGLE INTRAVITREAL INJECTION , BLOOD-AQUEOUS BARRIER , NEONATAL FC-RECEPTOR , HUMAN VITREOUS-HUMOR , COMPLEMENT REGULATORY PROTEINS , SERUM-ALBUMIN NANOPARTICLE S, LEBERS CONGENITAL AMAUROSIS",
author = "{del Amo}, {Eva M.} and Rimpel{\"a}, {Anna-Kaisa Irmeli} and Emma Heikkinen and Kari, {Otto K.} and Eva Ramsay and Tatu Lajunen and Mechthild Schmitt and Laura Pelkonen and Madhushree Bhattacharya and Dominique Richardson and Astrid Subrizi and Tiina Turunen and Mika Reinisalo and Jaakko Itkonen and Elisa Toropainen and Casteleijn, {Marco G.} and Heidi Kidron and Maxim Antopolsky and Kati-Sisko Vellonen and Marika Ruponen and Arto Urtti",
year = "2017",
month = "3",
doi = "10.1016/j.preteyeres.2016.12.001",
language = "English",
volume = "57",
pages = "134--185",
journal = "Progress in Retinal and Eye Research",
issn = "1350-9462",
publisher = "PERGAMON",

}

del Amo, EM, Rimpelä, A-KI, Heikkinen, E, Kari, OK, Ramsay, E, Lajunen, T, Schmitt, M, Pelkonen, L, Bhattacharya, M, Richardson, D, Subrizi, A, Turunen, T, Reinisalo, M, Itkonen, J, Toropainen, E, Casteleijn, MG, Kidron, H, Antopolsky, M, Vellonen, K-S, Ruponen, M & Urtti, A 2017, 'Pharmacokinetic aspects of retinal drug delivery', Progress in Retinal and Eye Research, vol. 57, s. 134-185. https://doi.org/10.1016/j.preteyeres.2016.12.001

Pharmacokinetic aspects of retinal drug delivery. / del Amo, Eva M.; Rimpelä, Anna-Kaisa Irmeli; Heikkinen, Emma ; Kari, Otto K.; Ramsay, Eva; Lajunen, Tatu; Schmitt, Mechthild; Pelkonen, Laura; Bhattacharya, Madhushree; Richardson, Dominique; Subrizi, Astrid ; Turunen, Tiina; Reinisalo, Mika; Itkonen, Jaakko ; Toropainen, Elisa; Casteleijn, Marco G. ; Kidron, Heidi ; Antopolsky, Maxim; Vellonen, Kati-Sisko; Ruponen, Marika; Urtti, Arto .

I: Progress in Retinal and Eye Research, Vol. 57, 03.2017, s. 134-185.

Forskningsoutput: TidskriftsbidragÖversiktsartikelVetenskapligPeer review

TY - JOUR

T1 - Pharmacokinetic aspects of retinal drug delivery

AU - del Amo, Eva M.

AU - Rimpelä, Anna-Kaisa Irmeli

AU - Heikkinen, Emma

AU - Kari, Otto K.

AU - Ramsay, Eva

AU - Lajunen, Tatu

AU - Schmitt, Mechthild

AU - Pelkonen, Laura

AU - Bhattacharya, Madhushree

AU - Richardson, Dominique

AU - Subrizi, Astrid

AU - Turunen, Tiina

AU - Reinisalo, Mika

AU - Itkonen, Jaakko

AU - Toropainen, Elisa

AU - Casteleijn, Marco G.

AU - Kidron, Heidi

AU - Antopolsky, Maxim

AU - Vellonen, Kati-Sisko

AU - Ruponen, Marika

AU - Urtti, Arto

PY - 2017/3

Y1 - 2017/3

N2 - Drug delivery to the posterior eye segment is an important challenge in ophthalmology, because many diseases affect the retina and choroid leading to impaired vision or blindness. Currently, intravitreal injections are the method of choice to administer drugs to the retina, but this approach is applicable only in selected cases (e.g. anti-VEGF antibodies and soluble receptors). There are two basic approaches that can be adopted to improve retinal drug delivery: prolonged and/or retina targeted delivery of intravitreal drugs and use of other routes of drug administration, such as periocular, suprachoroidal, sub-retinal, systemic, or topical. Properties of the administration route, drug and delivery system determine the efficacy and safety of these approaches. Pharmacokinetic and pharmacodynamic factors determine the required dosing rates and doses that are needed for drug action. In addition, tolerability factors limit the use of many materials in ocular drug delivery. This review article provides a critical discussion of retinal drug delivery, particularly from the pharmacokinetic point of view. This article does not include an extensive review of drug delivery technologies, because they have already been reviewed several times recently. Instead, we aim to provide a systematic and quantitative view on the pharmacokinetic factors in drug delivery to the posterior eye segment. This review is based on the literature and unpublished data from the authors' laboratory.

AB - Drug delivery to the posterior eye segment is an important challenge in ophthalmology, because many diseases affect the retina and choroid leading to impaired vision or blindness. Currently, intravitreal injections are the method of choice to administer drugs to the retina, but this approach is applicable only in selected cases (e.g. anti-VEGF antibodies and soluble receptors). There are two basic approaches that can be adopted to improve retinal drug delivery: prolonged and/or retina targeted delivery of intravitreal drugs and use of other routes of drug administration, such as periocular, suprachoroidal, sub-retinal, systemic, or topical. Properties of the administration route, drug and delivery system determine the efficacy and safety of these approaches. Pharmacokinetic and pharmacodynamic factors determine the required dosing rates and doses that are needed for drug action. In addition, tolerability factors limit the use of many materials in ocular drug delivery. This review article provides a critical discussion of retinal drug delivery, particularly from the pharmacokinetic point of view. This article does not include an extensive review of drug delivery technologies, because they have already been reviewed several times recently. Instead, we aim to provide a systematic and quantitative view on the pharmacokinetic factors in drug delivery to the posterior eye segment. This review is based on the literature and unpublished data from the authors' laboratory.

KW - 317 Pharmacy

KW - 3125 Otorhinolaryngology, ophthalmology

KW - Retina

KW - Vitreous

KW - Choroid

KW - Topical

KW - Intravitreal

KW - Sub-conjunctival

KW - Suprachoroidal

KW - Clearance

KW - Distribution

KW - Pharmacokinetic modeling

KW - Transport

KW - ENDOTHELIAL GROWTH-FACTOR

KW - PIGMENT EPITHELIAL-CELLS

KW - DIABETIC MACULAR EDEMA

KW - SINGLE INTRAVITREAL INJECTION

KW - BLOOD-AQUEOUS BARRIER

KW - NEONATAL FC-RECEPTOR

KW - HUMAN VITREOUS-HUMOR

KW - COMPLEMENT REGULATORY PROTEINS

KW - SERUM-ALBUMIN NANOPARTICLE S

KW - LEBERS CONGENITAL AMAUROSIS

U2 - 10.1016/j.preteyeres.2016.12.001

DO - 10.1016/j.preteyeres.2016.12.001

M3 - Review Article

VL - 57

SP - 134

EP - 185

JO - Progress in Retinal and Eye Research

JF - Progress in Retinal and Eye Research

SN - 1350-9462

ER -